Starpharma HoldingsASX:SPL +0.72%52 Gross Margin % is 96.15% as of Dec. 2025, which is 28% above its 10-year median of 75.08. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 737 Biotechnology companies, Starpharma Holdings ranks better than 84.94% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Starpharma Holdings had a gross margin of 96.15% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Starpharma Holdings Gross Margin % Related Terms
Starpharma Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SPL vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Starpharma Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Starpharma Holdings (ASX:SPL) has a Gross Margin % of 96.15% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Starpharma Holdings and its competitors. This is 28% above median its historical median of 75.08. Over the past decade, Starpharma Holdings' Gross Margin % has ranged from 40.71 to 92.38. According to the industry distribution chart, Starpharma Holdings ranks #111 out of 737 companies in the Biotechnology industry, placing it in the top 15.1%.
Is Starpharma Holdings' Gross Margin % too high?
Starpharma Holdings' current Gross Margin % of 96.15% is 28% above median its 10-year median of 75.08. Over the past 10 years, this metric has ranged from a low of 40.71 to a high of 92.38. The Biotechnology industry median Gross Margin % is 60.92. Starpharma Holdings' value of 96.15% is 57.8% above this industry median. Based on the distribution chart, Starpharma Holdings ranks #111 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #111 out of 737 companies for Gross Margin %. This places Starpharma Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Starpharma Holdings' value of 96.15% is 57.8% above this benchmark. Historically, Starpharma Holdings' own Gross Margin % has ranged from 40.71 to 92.38 over the past decade. While the company's 10-year median is 75.08 vs. the industry median of 60.92, Starpharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starpharma Holdings's current Gross Margin % of 96.15% is 57.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Starpharma Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starpharma Holdings's current Gross Margin % is 96.15%, which is 28% above median its own 10-year median of 75.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Gross Margin % is 96.15%, which is 28% above median its 10-year median of 75.08 and 57.8% above the Biotechnology industry median of 60.92. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Gross Margin % is 96.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
Gross Margin %: 96.15% (28% above median its 10-year median of 75.08)
GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
Industry Position: 57.8% above the Biotechnology median (#111 of 737)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
52GF Score
Get the complete analysis for ASX:SPL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
